While reporting financial results for the fourth quarter on Thursday, biopharmaceutical company Alkermes plc (ALKS) initiated its earnings and revenue guidance for the full-year 2021. This guidance reflects the anticipated growth of proprietary products and investment in strategic priorities for long-term value creation.
from RTT - Earnings https://ift.tt/3qaNE9j
via IFTTT
No comments:
Post a Comment